Patents by Inventor Zhiyuan CAO
Zhiyuan CAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944645Abstract: The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.Type: GrantFiled: September 30, 2021Date of Patent: April 2, 2024Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Zhiyuan Cao, Lei Xiao, Yuzhe Peng, Wei Ding, Wensheng Wang
-
Publication number: 20240092159Abstract: A hub motor assembly includes a traveling wheel, an outer rotor motor and a deceleration mechanism. An inside of the traveling wheel is provided with an inner ring gear, the outer rotor motor is arranged inside the traveling wheel, and an outside of the outer rotor motor is provided with an outer ring gear. The deceleration mechanism includes a planetary carrier and at least one planetary gear, and the planetary carrier is arranged between the traveling wheel and the outer rotor motor. The planetary gear is rotatably mounted on the planetary carrier, and the planetary gear is internally meshed with the outer ring gear and externally meshed with the inner ring gear. The outer rotor motor drives the planetary gear to rotate through the outer ring gear, and the planetary gear drives the inner ring gear to rotate and then drives the traveling wheel to rotate.Type: ApplicationFiled: August 15, 2023Publication date: March 21, 2024Applicant: Greenworks (Jiangsu) Co., Ltd.Inventors: Yuexun CAO, Zhiyuan LI, Naixin GAO, Tao WANG
-
Publication number: 20240098328Abstract: Provided are a video processing method and apparatus, and a device and a storage medium. The method comprises: when it is detected that an editing reference track of a video to be processed moves out of a video editing window, displaying a mask in the video editing window, wherein the editing reference track comprises a video editing track and/or an audio editing track; and then displaying, on the mask, the editing reference track of said video, wherein the editing reference track displayed on the mask is used for assisting a user with editing said video in the video editing window.Type: ApplicationFiled: November 28, 2023Publication date: March 21, 2024Inventors: Yan HE, Zhiyuan TAN, Hanxin MAI, Shaozu YU, Kun CAO
-
Patent number: 11932700Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.Type: GrantFiled: August 19, 2020Date of Patent: March 19, 2024Assignee: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi, Zhao Wu
-
Publication number: 20240075061Abstract: The present disclosure relates to compositions and methods for enhancing infiltration of lymphocytes into tumor tissue, enhancing anti-tumor lymphocyte activities in tumor microenvionment (TME), inhibiting regulatory lymphocyte (e.g., B and T cells) activities in TME, and/or long term benefit of cell therapies. For example, in a method of in vivo cell expansion, the method comprises administering an effective amount of cells comprising an antigen binding molecule to a subject; and administering an effective amount of presenting cells expressing a solid tumor antigen that the binding molecule binds.Type: ApplicationFiled: December 13, 2022Publication date: March 7, 2024Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Wensheng Wang, Dongqi Chen, Chengfei Pu, Zhao Wu, Lei Xiao, Zhiyuan Cao, Le Tian
-
Publication number: 20240058337Abstract: The present disclosure relates to compositions and methods for reducing side effects and/or enhancing cancer treatment that use modified immune cells expressing chimeric antigen receptors (CARs) or modified T cell receptors (TCRs). The modified immune cells, such as T cells or NK cells, can express CARs or TCRs targeting solid tumor antigens, white blood cell antigens like CD19, or bispecific CARs/TCRs targeting both. The methods include administering dasatinib to reduce the side effects associated with CAR T or TCR therapy and/or enhance cancer treatment. The modified cells can co-express additional therapeutic agents like cytokines.Type: ApplicationFiled: August 16, 2023Publication date: February 22, 2024Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, Zhao Wu, Chengfei Pu, Zhiyuan Cao, Dongqi Chen, Xiaobin Lu, Le Tian
-
Publication number: 20240024476Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. For example, the compositions include CAR T cells comprising an extracellular domain that binds FCR1, MSLN, GPC-3, ALPP, CD70, CLDN6, ROR1, CD205, ACPP, ADAM12, or CLDN18.2.Type: ApplicationFiled: January 6, 2022Publication date: January 25, 2024Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Zhiyuan Cao, Xiaogang Shen, Wensheng Wang, Beibei Jia, Dongqi Chen, Xiaoqiang Xu, Xudong Tang, Wei Ding, Xianyang Jiang, Yuzhe Peng, Guiting Han, Le Tian, Zhao Wu, Lei Xiao
-
Patent number: 11866494Abstract: The present disclosure relates to compositions and methods for enhancing CAR T therapy through uses of co-stimulation. Some embodiments relate to an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR) and an agent associated with a co-stimulatory molecule, the CAR comprising an intracellular domain of a costimulatory molecule.Type: GrantFiled: August 27, 2019Date of Patent: January 9, 2024Assignee: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Zhiyuan Cao, Chengfei Pu, Lei Xiao, Zhao Wu
-
Patent number: 11833174Abstract: Embodiments relate to a modified cell comprising a polynucleotide encoding a dominant negative form of Death receptor 5 (DR5). In embodiments, the modified cell further comprises a chimeric antigen receptor (CAR) and/or a modified TCR.Type: GrantFiled: September 17, 2020Date of Patent: December 5, 2023Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Zhiyuan Cao, Chengfei Pu, Dongqi Chen, Wei Ding
-
Patent number: 11834502Abstract: The present disclosure relates to a modified cell comprising a polynucleotide encoding a secretable scFv binding SIGLEC-15 and/or encoding a dominant negative form of CD44. In embodiments, the modified cell further comprises an antigen-binding molecule, which for example, is a CAR comprising an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain.Type: GrantFiled: July 22, 2021Date of Patent: December 5, 2023Assignee: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Zhiyuan Cao, Chengfei Pu, Lei Xiao
-
Patent number: 11823118Abstract: A logistics system for managing a network of independent delivery partners may include models to detect delivery defects. The models may generate defect scores for each onboarded delivery partner. The system may collect delivery data to continuously update the models. The updated models may score delivery partners for early detection of delivery defects and determine remediations steps. The system may train one or more models to determine the scores based on a terminating step of the delivery steps. The scores may indicate a likelihood the terminating step was caused by intentional action or by accident. The system may determine remediations steps based on the likelihood of intentional action.Type: GrantFiled: June 28, 2021Date of Patent: November 21, 2023Assignee: Amazon Technologies, Inc.Inventors: Zhiyuan Cao, Minghao Gai, Leah Autumn Thompkins, Arun Kumar Galba
-
Publication number: 20230322899Abstract: The present disclosure relates to a fusion protein and uses thereof. For example, the fusion protein comprises an extra-cellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is derived from a first molecule, and the intracellular domain is derived from a second molecule. The first molecule is different from the second molecule, and the second molecule comprises OX40, CD40, 4-1 BB, GITR, ICOS, CD28, CD27, HER2, EGFR, EL-10R, IL-12R, IL-18R1, IL-23R, GP130, or IL-15Ra.Type: ApplicationFiled: August 24, 2021Publication date: October 12, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Xiaogang Shen, Zhiyuan Cao, Lei Xiao, Beibei Jia, Le Tian
-
Publication number: 20230293691Abstract: The present disclosure relates to compositions and methods for treating a subject having cancer associated with melanoma-associated antigen 4 (MAGE-A4) peptide. The disclosure includes the embodiments relate to a chimeric antigen receptor (CAR) that binds MAGE-A4 peptide, a polynucleotide encoding a CAR that binds the MAGE-A4 peptide, a modified cell comprising a CAR that binds the MAGE-A4 peptide, and a population of modified cells comprising a CAR that binds the MAGE-A4 peptide.Type: ApplicationFiled: June 9, 2021Publication date: September 21, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Xiaogang Shen, Dongqi Chen, Beibei Jia, Le Tian
-
Patent number: 11739136Abstract: Embodiments relate to a modified cell comprising a chimeric antigen receptor (CAR) and a dominant negative form of PD-1, wherein the dominant negative form of PD-1 lacks a functional PD-1 intracellular domain for PD-1/PD-L1 signal transduction, and the CAR comprises an antigen binding domain, a transmembrane domain, a co-stimulatory domain, and a CD3 zeta domain. The dominant negative form of PD-1 is regulated by an inducible gene expression system.Type: GrantFiled: March 18, 2020Date of Patent: August 29, 2023Assignee: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Chengfei Pu, Zhiyuan Cao, Lei Xiao
-
Publication number: 20230226113Abstract: The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFN?.Type: ApplicationFiled: March 31, 2023Publication date: July 20, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Yang Li, Zhiyuan Cao, Wei Ding, Xianyang Jiang, Chengfei Pu, Le Tian, Christopher Ballas, Zhao Wu, Lei Xiao
-
Patent number: 11701385Abstract: Embodiments relate to a modified cell comprising an antigen binding molecule, and the expression and/or function of one or more genes in the modified cell has been enhanced or reduced or eliminated. The one or more genes include CXCR3, SLC1A3, YAP, TIGIT, S1P1, and IL-35. In embodiments, the cell is a T cell, a dendritic cell, a NK cell, or a macrophage cell. In embodiments, the antigen binding molecule comprises a chimeric antigen receptor (CAR) and/or the second antigen binding molecule is a T Cell Receptor (TCR).Type: GrantFiled: August 29, 2019Date of Patent: July 18, 2023Assignee: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Zhiyuan Cao, Chengfei Pu, Lei Xiao, Zhao Wu
-
Publication number: 20230201440Abstract: The present disclosure relates to a system for immune therapy, the system comprising a sample processing module configured to obtain whole blood from a subject; a cell incubation module configured to activate blood cells of the whole blood and/or introduce a vector into the blood cells of the whole blood; and a cell infusion module configured to infuse at least a portion of the whole blood to the subject, wherein the blood cells comprise CD3+ cells, NK cells, myeloid cells, and neutrophils.Type: ApplicationFiled: May 7, 2021Publication date: June 29, 2023Inventors: Lei Xiao, Zhiyuan Cao, Zhao Wu, Chengfei PU, Xiaogang Shen, Haiyang Tang, Le Tian
-
Publication number: 20230201258Abstract: The present disclosure relates to compositions and methods for enhancing cell response and/or expanding chimeric antigen receptor (CAR) cells and/or maintenance in vivo and/or in vitro. In embodiments, the method comprises obtaining CAR T cells comprising a CAR comprising a binding domain that binds a solid tumor antigen, a transmembrane domain, and an intracellular domain; and contacting the CART cells with white blood cells and a bispecific antibody, such as a Bispecific T cell engager (BiTE®), thereby activating the CAR T cells, wherein the level of activation of the CAR T cells is higher than the level of activation of CAR T ells that are contacted with B cells without the bispecific antibody. The bispecific antibody comprises a first binding domain binding CD3 and a second binding domain binding CD19, CD20, CD22, or BCMA.Type: ApplicationFiled: April 21, 2021Publication date: June 29, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Lei Xiao, Jingrui Liu, Junkai Peng, Le Tian, Xiaogang Shen, Zhiyuan Cao, Zhao Wu
-
Patent number: 11633427Abstract: The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFN?.Type: GrantFiled: February 4, 2022Date of Patent: April 25, 2023Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Yang Li, Zhiyuan Cao, Wei Ding, Xianyang Jiang, Chengfei Pu, Le Tian, Christopher Ballas, Zhao Wu, Lei Xiao
-
Publication number: 20230074145Abstract: The compositions and methods described herein are directed to treating solid tumors using CAR T therapy and/or antibodies targeting GCC. The compositions include CAR comprising an extracellular domain that binds GCC.Type: ApplicationFiled: August 23, 2022Publication date: March 9, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Zhiyuan Cao, Yuzhe Peng, Lei Xiao, Zhao Wu, Le Tian